---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-044934"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:33:36.222521+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma raises $110M in underwritten public offering of 7.87M shares at $13.98/share

## Summary
- Offering of 7,868,383 shares at $13.98 per share; gross proceeds approximately $110.0 million.
- Underwriters include Leerink Partners and TD Securities; closing expected February 11, 2026.
- Proceeds to fund research, clinical development, manufacturing, and general corporate purposes.
- Combined with existing cash, total capital resources estimated at $251.4 million; cash runway into Q2 2028.
- Offering made under existing shelf registration statement; customary underwriting agreement terms.

## SEC filing metadata
- accession: 0001193125-26-044934
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000119312526044934/0001193125-26-044934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000119312526044934/d52363d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-044934
- JSON: https://secwatch.observer/filing/0001193125-26-044934.json
- Plain text: https://secwatch.observer/filing/0001193125-26-044934.txt

## Key facts
- Material Agreements
  SUTRO BIOPHARMA, INC. entered into Underwriting Agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein valued at approximately $110.0 million (effective 2026-02-09).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein
  - Value: approximately $110.0 million
  - Effective: 2026-02-09
  source text: On February 9, 2026, Sutro Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000119312526044934/0001193125-26-044934-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.